Dolutegravir

Magnesium (hydroxide)

A spacing between the drugs is required.

No pharmaceutical opinion available for this interaction.

Mechanism

Cations by chelation may reduce the absorption of Dolutegravir.

Dolutegravir

Pharmacodynamic effects

Possible decrease of clinical efficacy.

Recommendations

Tivicay or Triumeq : administer 2 hours before or 6 hours after the antacid.

Juluca : administer 4 hours before or 6 hours after the antacid.

Monitor for clinical efficacy.

Alternative solution(s)

Magnesium (hydroxide)

Pharmacodynamic effects

Recommendations

Avoid association, if possible.

Alternative solution(s)

For Tivicay or Triumeq : H2 receptor antagonists or proton pump inhibitors. For Juluca : H2 receptor antagonists administered 4 hours or 12 hours after Juluca. Proton Pump Inhibitors contraindicated.

Monitor

Tests

CD4+

Viral load HIV

Dolutegravir plasma level

Pharmacokinetic parameters

Comment

See also antiacids + dolutegravir.

Reference
  • 2868
    Dolutegravir (Tivicay), ViiV Healthcare, Quebec, Canada, 27 août 2018.
  • 2858
    Dolutegravir (Tivicay), US Prescribing Information, ViiV Healthcare, August 2013.
  • 3120
    Dolutégravir/abacavir/lamivudine (Triumeq), ViiV Healthcare, Québec, Canada, 27 août 2018.
  • 3441
    Dolutegravir/Rilpivirine (Juluca), ViiV Healthcare ULC, Quebec, Canada, 27 août 2018.